Listed by the USPTO as CHONG, YONG SOO
Tech Center 1600 • Art Units: 1617 1623 1627
This examiner grants 44% of resolved cases
CHONG, YONG SOO is assigned to Tech Center 1600 and Art Unit 1617. The record covers 894 resolved cases, with an allowance rate of 43.8% and a median of 1426 days to allowance. The interview lift is 41.7%, indicating a meaningful association between interviews and allowance outcomes. The substantial case volume makes these measures useful for planning before substantive responses are prepared.
Top companies include Schedule 1 Therapeutics Inc., Metabolic Technologies, LLC, and The Regents of the University of California. The leading firms are Dentons Davis Brown PC, GOODWIN PROCTER LLP, and POLSINELLI PC (Main Customer Number). These records provide context for biotechnology and academic matters. Counsel may consider purposeful examiner interviews alongside detailed claim analysis and longer-term docket management.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17760090 | ELONGATION FACTOR 1-ALPHA INHIBITORS AND USES THEREOF | Non-Final OA | The Regents of the University of California |
| 19065116 | DOSE REGIMEN OF VICASINABIN | Non-Final OA | Hoffmann-La Roche Inc. |
| 18566259 | SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF | Final Rejection | NOVARTIS PHARMA AG |
| 18740833 | SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY | Non-Final OA | The Penn State Research Foundation |
| 18553840 | DONOR-ACCEPTOR CONJUGATED OLIGOELECTROLYTES FOR CELL LABELLING AND METHODS THEREOF | Non-Final OA | National University of Singapore |
| 18785196 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Final Rejection | OTSUKA PHARMACEUTICAL CO., LTD. |
| 18866386 | ARGINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Non-Final OA | Daewoong Pharmaceutical Co., Ltd. |
| 18247561 | RILUZOLE FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Final Rejection | Icahn School of Medicine at Mount Sinai |
| 18272176 | METHODS FOR OPTIMIZING CFTR-MODULATOR THERAPY | Final Rejection | Children's Hospital Medical Center |
| 18835242 | METHODS OF PREPARING AND CRYSTALLINE FORMS OF (6A,12A)-17-AMINO-12-METHYL-6,15-BIS(TRIFLUOROMETHYL)-13,19-DIOXA-3,4,18-TRIAZATRICYCLO[12.3.1.12,5]NONADECA-1(18),2,4,14,16-PENTAEN-6-OL | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18260721 | USP13 INHIBITORS AND METHODS OF USE THEREOF | Non-Final OA | GEORGETOWN UNIVERSITY |
| 18254315 | COMPOUNDS FOR TREATING SEGMENTAL PROGEROID SYNDROMES | Non-Final OA | École Nationale Supérieure de Chimie de Montpellier |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy43.8% of resolved applications examined by Yong Soo Chong were allowed (894 resolved cases), compared with 34.2% across Art Unit 1617 over the last five years.
This examiner's interview lift is +41.7 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Yong Soo Chong took 1,426 days on average from filing to allowance.
Yong Soo Chong examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).